Aptose's Cash Dries Up, Nasdaq Delisting Confirmed Amid Mounting Losses

Ticker: APTOF · Form: 10-Q · Filed: Aug 13, 2025 · CIK: 882361

Sentiment: bearish

Topics: Biotechnology, Oncology, Going Concern, Liquidity Crisis, Nasdaq Delisting, Clinical Stage, Shareholder Deficit

Related Tickers: APTOF

TL;DR

**Aptose is on life support; cash is gone, Nasdaq delisted, and they're burning through capital with no clear path to solvency.**

AI Summary

Aptose Biosciences Inc. reported a net loss of $7.043 million for the three months ended June 30, 2025, a slight improvement from the $7.252 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $12.586 million, significantly lower than the $16.892 million loss in the prior year. Research and development expenses decreased to $3.298 million for the quarter from $4.413 million, and to $5.662 million for the six months from $10.858 million, indicating reduced clinical activity or cost management. General and administrative expenses, however, increased to $3.623 million for the quarter from $2.932 million, and to $6.720 million for the six months from $6.247 million. The company's cash and cash equivalents plummeted from $6.152 million at December 31, 2024, to $553 thousand by June 30, 2025. Total current assets decreased from $9.530 million to $3.271 million, while total current liabilities surged from $4.477 million to $9.000 million, resulting in a negative working capital of $5.729 million. A significant risk highlighted is the company's delisting from Nasdaq due to failure to meet the minimum equity requirement of $2.5 million by March 31, 2025, and substantial doubt about its ability to continue as a going concern.

Why It Matters

This filing reveals Aptose Biosciences is in a precarious financial state, with cash and cash equivalents dropping to $553 thousand and a negative working capital of $5.729 million. For investors, this signals extreme dilution risk from future capital raises or potential insolvency, especially given the Nasdaq delisting. Employees face job insecurity as the company struggles to fund operations. Customers and the broader market will see delays or cessation of development for its oncology drug candidates, tuspetinib and luxeptinib, impacting future treatment options in hematologic cancers. Competitively, this weakens Aptose's position against better-capitalized biotech firms in the oncology space.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt about the Company's ability to continue as a going concern exists" and reported cash and cash equivalents of only $553 thousand as of June 30, 2025, down from $6.152 million at December 31, 2024. Furthermore, Aptose was delisted from Nasdaq for failing to meet the $2.5 million minimum equity requirement by March 31, 2025, severely limiting its access to capital markets.

Analyst Insight

Investors should avoid Aptose Biosciences Inc. (APTOF) given the severe liquidity crisis, negative working capital of $5.729 million, and the explicit 'going concern' warning. The Nasdaq delisting further complicates any potential recovery or future capital raises, making this a highly speculative and risky investment.

Financial Highlights

net Income
-$7.043M
cash Position
$553K

Key Numbers

Key Players & Entities

FAQ

What is Aptose Biosciences Inc.'s current cash position?

Aptose Biosciences Inc. reported cash and cash equivalents of only $553 thousand as of June 30, 2025. This represents a significant decrease from $6.152 million at December 31, 2024.

Why was Aptose Biosciences Inc. delisted from Nasdaq?

Aptose Biosciences Inc. was delisted from Nasdaq because it failed to comply with Nasdaq's minimum equity requirement of $2.5 million by March 31, 2025. This indicates a severe financial weakness.

What is the net loss for Aptose Biosciences Inc. for the first half of 2025?

For the six months ended June 30, 2025, Aptose Biosciences Inc. reported a net loss of $12.586 million. This is an improvement compared to the $16.892 million net loss for the same period in 2024.

Does Aptose Biosciences Inc. have enough capital to continue operations?

No, the filing explicitly states that "substantial doubt about the Company's ability to continue as a going concern exists" and that the company "does not have sufficient cash to fund operations."

What are Aptose Biosciences Inc.'s primary drug candidates?

Aptose Biosciences Inc. is advancing two clinical-stage investigational products for hematological malignancies: tuspetinib, an oral myeloid kinase inhibitor, and luxeptinib, an oral dual lymphoid and myeloid kinase inhibitor.

How have Aptose Biosciences Inc.'s research and development expenses changed?

Research and development expenses for Aptose Biosciences Inc. decreased to $3.298 million for the three months ended June 30, 2025, from $4.413 million in the prior year. For the six months, they dropped to $5.662 million from $10.858 million.

What is Aptose Biosciences Inc.'s accumulated deficit?

As of June 30, 2025, Aptose Biosciences Inc. had an accumulated deficit of $553.6 million. This figure increased from $541.0 million at December 31, 2024, reflecting ongoing losses.

What is the impact of the reverse stock split on Aptose Biosciences Inc.'s shares?

On February 26, 2025, Aptose Biosciences Inc. effected a 1-for-30 reverse stock split. All issued and outstanding common shares, stock options, and warrants have been retroactively adjusted to reflect this for all periods presented.

What is Aptose Biosciences Inc.'s strategy for raising additional capital?

Management plans to raise additional funds through debt or other financing activities, including collaborations or reorganization to reduce operational expenses. However, they acknowledge no assurance of obtaining liquidity on acceptable terms, if at all.

How has Aptose Biosciences Inc.'s working capital changed?

Aptose Biosciences Inc.'s current assets less current liabilities resulted in a negative $5.7 million as of June 30, 2025. This is a significant deterioration from a positive $5.1 million at December 31, 2024.

Risk Factors

Industry Context

The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing to fund operations until a product gains market approval. Aptose operates in a highly competitive landscape where successful clinical trial outcomes and effective capital management are critical for survival and growth.

Regulatory Implications

Failure to meet Nasdaq's minimum equity requirement poses a significant regulatory risk, leading to potential delisting. This could severely impact the company's ability to raise capital and its overall market standing. Continued scrutiny on financial health is expected.

What Investors Should Do

  1. Monitor cash burn rate and future financing activities.
  2. Assess the impact of reduced R&D spending.
  3. Evaluate the likelihood of continued operations.

Key Dates

Glossary

Going Concern
An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. If substantial doubt exists, it must be disclosed. (Aptose faces substantial doubt about its ability to continue as a going concern, indicating severe financial instability.)
Working Capital
The difference between a company's current assets and current liabilities. Positive working capital indicates a company's ability to meet its short-term obligations. (Aptose has negative working capital of $5.729 million, meaning its short-term liabilities exceed its short-term assets, posing a liquidity risk.)
Accumulated Deficit
The cumulative net losses of a company since its inception that have not been offset by net income. It represents a negative retained earnings balance. (Aptose's accumulated deficit increased to $553.6 million, reflecting its ongoing history of losses.)
Delisting
The removal of a company's stock from a stock exchange, often due to failure to meet listing requirements. (Aptose is at risk of delisting from Nasdaq due to failing to meet equity requirements, which would severely impact its stock liquidity and investor access.)

Year-Over-Year Comparison

Compared to the prior year, Aptose Biosciences has seen a reduction in its net loss for both the quarter ($7.043M vs $7.252M) and the six-month period ($12.586M vs $16.892M), primarily driven by a significant decrease in R&D expenses. However, this cost-saving measure is overshadowed by a severe deterioration in liquidity, with cash and cash equivalents plummeting and working capital turning negative. Furthermore, G&A expenses have increased, and the company faces delisting from Nasdaq, presenting new and heightened financial and operational risks not as prominent in the prior period.

Filing Stats: 4,441 words · 18 min read · ~15 pages · Grade level 17.3 · Accepted 2025-08-13 16:45:48

Filing Documents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 4

– Financial Statements

Item 1 – Financial Statements 4

– Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations 20

– Qualitative and Quantitative Disclosures about Market Risk

Item 3 – Qualitative and Quantitative Disclosures about Market Risk 39

– Controls and Procedures

Item 4 – Controls and Procedures 39

—OTHER INFORMATION

PART II—OTHER INFORMATION 40

– Legal Proceedings

Item 1 – Legal Proceedings 40

– Risk Factors

Item 1A – Risk Factors 40

– Exhibits

Item 6 – Exhibits 42

Signatures

Signatures 43 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities law, which we collectively refer to as "forward-looking statements". Such forward-looking statements reflect our current beliefs and are based on information currently available to us. In some cases, forward-looking statements can be identified by terminology such as "may," "would," "could," "will," "should," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "continue," "hope," "foresee" or the negative of these terms or other similar expressions concerning matters that are not historical facts. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to continue as a going concern; our need to raise substantial additional capital in the near future and our ability to raise such funds when needed and on acceptable terms; if a financing is completed, it may not be a large enough financing to fully fund the company operations; our suppliers or clinical sites may choose to implement work stoppage on key programs, change the terms of contracts or terminate contracts for key programs; our conversations with partners to renegotiate existing product license agreements may not be successful; our lack of product revenues and net losses and a history of operating losses; our ability to meet the continued listing requirements of the TSX and the listing requirements to relist on Nasdaq; our early stage of development, particularly the inherent risks and uncertainties associated with (i) developing new drug candidates generally,

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

– FINA NCIAL STATEMENTS

ITEM 1 – FINA NCIAL STATEMENTS Condensed Consolidated Interim Financial Statements (Unaudited) APTOSE BIOSCIENCES INC. For the three and six months ended June 30, 2025 and 2024 4 APTOSE BIOSCIENCES INC. Condensed Consolidated Interim Statements of Financial Position (Expressed in thousands of US dollars, except for common share data) (unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 553 $ 6,152 Restricted cash equivalents, current 745 555 Prepaid expenses 1,857 2,253 Other current assets 116 570 Total current assets 3,271 9,530 Non-current assets: Property and equipment 19 26 Right-of-use assets, operating leases 377 571 Other long-term assets 1,924 — Total non-current assets 2,320 597 Total assets $ 5,591 $ 10,127 Liabilities and Shareholders' Deficit Current liabilities: Accounts payable $ 2,879 $ 1,258 Accrued liabilities 5,414 2,773 Current portion of lease liability, operating leases 413 428 Interest on related party loan payable 294 18 Total current liabilities 9,000 4,477 Non-current liabilities: Lease liability, operating leases — 193 Loan payable to related party 10,962 10,000 Total non-current liabilities 10,962 10,193 Total liabilities 19,962 14,670 Shareholders' deficit: Share capital: Common shares, no par value, unlimited authorized shares, 2,552,429 and 2,006,028 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 459,771 457,404 Additional paid-in capital 83,727 83,336 Accumulated other comprehensive loss ( 4,316 ) ( 4,316 ) Accumulated deficit ( 553,553 ) ( 540,967 ) Total shareholders' deficit ( 14,371 ) ( 4,543 ) Total liabilities and shareholders' deficit $ 5,591 $ 10,127 The accompanying notes are an integral part of these condensed consolidated interim

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing